OncoMatch/Clinical Trials/NCT07153445
Neoadjuvant Treatment With Atezolizumab and Atezolizumab as Maintenance for the Treatment of Stage III Non Small-Cell Lung Cancer (NSCLC)
Is NCT07153445 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Atezolizumab and Paclitaxel for non small cell lung cancer.
Treatment: Atezolizumab · Paclitaxel · Carboplatin — This is an open-label, phase II, multi-centre clinical trial. 97 Patients with stage IIIA and IIIB non-small cell lung cancer will be enrolled. The treatment is Atezolizumab + Paclitaxel + Carboplatin 3 cycles as neoadjuvant/induction treatment. After the induction treatment every patient will be evaluated by a multidisciplinary team in each participant hospital to decide if the patient is candidate for surgery or not. Depending on the decision each patient will be treated in a different way. The primary objective is to evaluate the Progression free survival (PFS). The total trial duration will be 10 years approximately. Patient accrual is expected to be completed within 2 years. Two years of treatment, 5 years of follow up, and 4-6 months of close-out.
Check if I qualifyExtracted eligibility criteria
Cancer type
Small Cell Lung Cancer
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: EGFR mutation
Patients mutation or an amplification in the EGFRgene
Required: EGFR amplification
Patients mutation or an amplification in the EGFRgene
Required: ALK fusion
ALK fusion oncogene
Required: STK11 ligand alteration
Known STK-11 ligand alterations
Required: MDM2 amplification
MDM2 amplifications
Required: ROS1 translocation
ROS1 translocations
Disease stage
Required: Stage IIIA, IIIB
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: antineoplastic drugs
Patients that receive previous treatment with antineoplasic drugs
Cannot have received: chest radiotherapy
Patients that receive previous treatment with ... chest radiotherapy
Cannot have received: surgery for lung cancer
Patients that receive previous ... surgery for lung cancer
Lab requirements
Blood counts
Kidney function
Liver function
Adequate hematologic and organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify